VIRTUAL CONFERENCE PROGRAMS

Add Virtual Dates to Outlook


6th Annual OPT Congress VIRTUAL

March 24 - 25, 2021

Location: VIRTUAL, all times EDT

NEW for 2021: We are offering you the flexibility of either a 1 day or 2 day pass, allowing you to tailor this event to your specific needs.

OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Join us in March when we bring together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers. Optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.

We are pleased to announce record attendance in 2020 - join this growing community and sign up today!



2020 Keynote Speakers

Brett Monia, PhD
CEO, Ionis Pharmaceuticals

Edward Kaye, MD
CEO, Stoke Therapeutics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
CTO, Sirnaomics

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi; Scientific Managing Director, COMPACT Consortium

Marvin Caruthers, PhD
Distinguished Professor, University of Colorado

Phil Baran, PhD
Professor, Department of Chemistry, Scripps Research

Jesse Faber
Senior Process Engineer III, ASO Process Engineering and Manufacturing, Biogen

Francis Ring

Francis Ring
Assistant Director, Manufacturing & Operations, Ionis Pharmaceuticals

Patrick Lu, PhD
President & CEO, Sirnaomics

Elena Feinstein, MD, PhD
CSO, Quark Pharmaceuticals

David Corey, PhD
Professor, Department of Pharmacology, UT Southwestern



With thanks to our Executive Advisory Board

Dmitry Samarsky, PhD
CTO, Sirnaomics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi


65%
of Attendees
from Biotech
15%
of Attendees
from Pharma
130+
Unique
Organizations
10+
Hours of
Networking